Brokers Set Expectations for Zoetis’ Q2 Earnings (NYSE:ZTS)

Zoetis Inc. (NYSE:ZTS) – Equities researchers at Leerink Partnrs decreased their Q2 2025 earnings per share (EPS) estimates for shares of Zoetis in a report released on Tuesday, May 6th. Leerink Partnrs analyst D. Clark now anticipates that the company will post earnings per share of $1.60 for the quarter, down from their previous estimate of $1.61. The consensus estimate for Zoetis’ current full-year earnings is $6.07 per share.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter last year, the company earned $1.38 EPS. The firm’s revenue was up 1.4% compared to the same quarter last year.

Several other research analysts have also recently weighed in on ZTS. Morgan Stanley decreased their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. UBS Group lowered their price target on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday. Piper Sandler lifted their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Finally, StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Zoetis presently has an average rating of “Buy” and an average price target of $212.13.

Zoetis Stock Performance

NYSE ZTS opened at $159.96 on Thursday. The company’s 50 day simple moving average is $157.27 and its two-hundred day simple moving average is $166.22. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. Zoetis has a 1 year low of $139.70 and a 1 year high of $200.33. The stock has a market capitalization of $71.37 billion, a PE ratio of 29.24, a P/E/G ratio of 2.78 and a beta of 0.94.

Insiders Place Their Bets

In related news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the transaction, the executive vice president now owns 16,107 shares in the company, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,862 shares of company stock valued at $312,254. 0.18% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zoetis

Several institutional investors and hedge funds have recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC raised its holdings in Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after buying an additional 140 shares during the last quarter. Rakuten Securities Inc. increased its position in shares of Zoetis by 5,533.3% in the fourth quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after acquiring an additional 166 shares during the period. Navigoe LLC bought a new position in shares of Zoetis during the fourth quarter valued at about $30,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. grew its stake in shares of Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company’s stock worth $42,000 after purchasing an additional 120 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.